HOME
RESOURCE LIBRARY
LEARNING COMMUNITY
FOR PATIENTS
NEWS & EVENTS
News
Event Calendar
Event Recordings
ABOUT
Overview
Quality Initiatives
Practice Map
Team
Contact Us
LEARN
Video
Publications
Care For All
LCD Patient Simulator
SPECIALTY CARE
Nephrology
Endocrinology
COVERAGE CHECKER
ADMIN PORTAL
PATIENT DATA DASHBOARD

NEWS & EVENTS

NewsEvent CalendarEvent Recordings

ABOUT

OverviewQuality InitiativesPractice MapTeamContact Us

LEARN

VideoPublicationsCare For AllLCD Patient Simulator

SPECIALTY CARE

NephrologyEndocrinology
COVERAGE CHECKER
ADMIN PORTAL
PATIENT DATA DASHBOARD
MCT2D Logo
RESOURCE LIBRARYLEARNING COMMUNITYFOR PATIENTS
Search Icon

Dosing Information for SGLT2 Inhibitors and Incretin Mimetics for Type 2 Diabetes

DOWNLOAD RESOURCE

Updated: 05/13/25

Key dosing information for SGLT2-I and Incretin Mimetics (GLP-1 RAs and GLP-1 RA/GIP) including dose escalation, pen and needle RX considerations, proven benefits for ASCVD, CKD, HFrEF, HFpEF, and DKD.
MCT2D Newsletter

Subscribe to the MCT2D Newsletter

Once per month we deliver news, updates, events, and more directly to you!

ccteam@mct2d.org

ResourcesPoint of CareMy BookmarksMembersEventsNewsPatientsSpecialty CareNephrology
AboutOverviewQuality InitiativesJoinHealth EquityTeam
A nonprofit and independent licensee of the Blue Cross Blue Shield Association

Support for The Michigan Collaborative for Type 2 Diabetes (MCT2D) is provided by Blue Cross Blue Shield of Michigan as part of the BCBSM Value Partnerships program.

Although Blue Cross Blue Shield of Michigan and MCT2D work collaboratively, the opinions, beliefs and viewpoints expressed by the author do not necessarily reflect the opinions, beliefs and viewpoints of BCBSM or any of its employees.